514 related articles for article (PubMed ID: 24719405)
21. A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.
Fehniger TA; Miller JS; Stuart RK; Cooley S; Salhotra A; Curtsinger J; Westervelt P; DiPersio JF; Hillman TM; Silver N; Szarek M; Gorelik L; Lowdell MW; Rowinsky E
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1581-1589. PubMed ID: 29597002
[TBL] [Abstract][Full Text] [Related]
22. Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML.
Björklund AT; Carlsten M; Sohlberg E; Liu LL; Clancy T; Karimi M; Cooley S; Miller JS; Klimkowska M; Schaffer M; Watz E; Wikström K; Blomberg P; Wahlin BE; Palma M; Hansson L; Ljungman P; Hellström-Lindberg E; Ljunggren HG; Malmberg KJ
Clin Cancer Res; 2018 Apr; 24(8):1834-1844. PubMed ID: 29444931
[No Abstract] [Full Text] [Related]
23. Therapeutic applications: natural killer cells in the clinic.
Miller JS
Hematology Am Soc Hematol Educ Program; 2013; 2013():247-53. PubMed ID: 24319187
[TBL] [Abstract][Full Text] [Related]
24. Diphtheria toxin-based recombinant murine IL-2 fusion toxin for depleting murine regulatory T cells in vivo.
Wei M; Marino J; Trowell A; Zhang H; Stromp Peraino J; Rajasekera PV; Madsen JC; Sachs DH; Huang CA; Benichou G; Wang Z
Protein Eng Des Sel; 2014 Sep; 27(9):289-95. PubMed ID: 25147093
[TBL] [Abstract][Full Text] [Related]
25. Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia.
Zhou Q; Bucher C; Munger ME; Highfill SL; Tolar J; Munn DH; Levine BL; Riddle M; June CH; Vallera DA; Weigel BJ; Blazar BR
Blood; 2009 Oct; 114(18):3793-802. PubMed ID: 19724059
[TBL] [Abstract][Full Text] [Related]
26. Larger Size of Donor Alloreactive NK Cell Repertoire Correlates with Better Response to NK Cell Immunotherapy in Elderly Acute Myeloid Leukemia Patients.
Curti A; Ruggeri L; Parisi S; Bontadini A; Dan E; Motta MR; Rizzi S; Trabanelli S; Ocadlikova D; Lecciso M; Giudice V; Fruet F; Urbani E; Papayannidis C; Martinelli G; Bandini G; Bonifazi F; Lewis RE; Cavo M; Velardi A; Lemoli RM
Clin Cancer Res; 2016 Apr; 22(8):1914-21. PubMed ID: 26787753
[TBL] [Abstract][Full Text] [Related]
27. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.
Miller JS; Soignier Y; Panoskaltsis-Mortari A; McNearney SA; Yun GH; Fautsch SK; McKenna D; Le C; Defor TE; Burns LJ; Orchard PJ; Blazar BR; Wagner JE; Slungaard A; Weisdorf DJ; Okazaki IJ; McGlave PB
Blood; 2005 Apr; 105(8):3051-7. PubMed ID: 15632206
[TBL] [Abstract][Full Text] [Related]
28. Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
Choi I; Yoon SR; Park SY; Kim H; Jung SJ; Jang YJ; Kang M; Yeom YI; Lee JL; Kim DY; Lee YS; Kang YA; Jeon M; Seol M; Lee JH; Lee JH; Kim HJ; Yun SC; Lee KH
Biol Blood Marrow Transplant; 2014 May; 20(5):696-704. PubMed ID: 24525278
[TBL] [Abstract][Full Text] [Related]
29. Diphtheria toxin-based bivalent human IL-2 fusion toxin with improved efficacy for targeting human CD25(+) cells.
Peraino JS; Zhang H; Rajasekera PV; Wei M; Madsen JC; Sachs DH; Huang CA; Wang Z
J Immunol Methods; 2014 Mar; 405():57-66. PubMed ID: 24462799
[TBL] [Abstract][Full Text] [Related]
30. Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy.
Berrien-Elliott MM; Becker-Hapak M; Cashen AF; Jacobs M; Wong P; Foster M; McClain E; Desai S; Pence P; Cooley S; Brunstein C; Gao F; Abboud CN; Uy GL; Westervelt P; Jacoby MA; Pusic I; Stockerl-Goldstein KE; Schroeder MA; DiPersio JF; Soon-Shiong P; Miller JS; Fehniger TA
Blood; 2022 Feb; 139(8):1177-1183. PubMed ID: 34797911
[TBL] [Abstract][Full Text] [Related]
31. Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia.
Vela M; Corral D; Carrasco P; Fernández L; Valentín J; González B; Escudero A; Balas A; de Paz R; Torres J; Leivas A; Martinez-Lopez J; Pérez-Martínez A
Cancer Lett; 2018 May; 422():107-117. PubMed ID: 29477379
[TBL] [Abstract][Full Text] [Related]
32. Haploidentical stem cell transplantation for acute leukemia.
Aversa F; Terenzi A; Felicini R; Carotti A; Falcinelli F; Tabilio A; Velardi A; Martelli MF
Int J Hematol; 2002 Aug; 76 Suppl 1():165-8. PubMed ID: 12430847
[TBL] [Abstract][Full Text] [Related]
33. A pilot study of denileukin diftitox (DD) in combination with high-dose interleukin-2 (IL-2) for patients with metastatic renal cell carcinoma (RCC).
Atchison E; Eklund J; Martone B; Wang L; Gidron A; Macvicar G; Rademaker A; Goolsby C; Marszalek L; Kozlowski J; Smith N; Kuzel TM
J Immunother; 2010 Sep; 33(7):716-22. PubMed ID: 20664355
[TBL] [Abstract][Full Text] [Related]
34. NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.
Martner A; Rydström A; Riise RE; Aurelius J; Brune M; Foà R; Hellstrand K; Thorén FB
Oncotarget; 2015 Dec; 6(40):42569-74. PubMed ID: 26544512
[TBL] [Abstract][Full Text] [Related]
35. The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission.
Blaise D; Attal M; Pico JL; Reiffers J; Stoppa AM; Bellanger C; Molina L; Nedellec G; Vernant JP; Legros M; Gabus R; Huguet F; Brandely M; Hercend T; Olive D; Maraninchi D
Leuk Lymphoma; 1997 May; 25(5-6):469-78. PubMed ID: 9250817
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia.
Frankel AE; Fleming DR; Hall PD; Powell BL; Black JH; Leftwich C; Gartenhaus R
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3555-61. PubMed ID: 14506141
[TBL] [Abstract][Full Text] [Related]
37. Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice.
Yalcintepe L; Frankel AE; Hogge DE
Blood; 2006 Nov; 108(10):3530-7. PubMed ID: 16882709
[TBL] [Abstract][Full Text] [Related]
38. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.
Siegler U; Kalberer CP; Nowbakht P; Sendelov S; Meyer-Monard S; Wodnar-Filipowicz A
Leukemia; 2005 Dec; 19(12):2215-22. PubMed ID: 16224486
[TBL] [Abstract][Full Text] [Related]
39. Differential effects of denileukin diftitox IL-2 immunotoxin on NK and regulatory T cells in nonhuman primates.
Yamada Y; Aoyama A; Tocco G; Boskovic S; Nadazdin O; Alessandrini A; Madsen JC; Cosimi AB; Benichou G; Kawai T
J Immunol; 2012 Jun; 188(12):6063-70. PubMed ID: 22586034
[TBL] [Abstract][Full Text] [Related]
40. Generation of cytotoxic NK cells in peripheral blood and bone marrow of patients with acute myelogenous leukemia after continuous infusion with recombinant interleukin-2.
Lotzová E; Savary CA; Schachner JR; Huh JO; McCredie K
Am J Hematol; 1991 Jun; 37(2):88-99. PubMed ID: 2069169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
